Conolidine’s analgesic outcomes stem from its conversation with non-opioid pain pathways. Not like opioids, which bind to µ-opioid receptors during the central nervous system, conolidine modulates alternate molecular targets. A Science Innovations research discovered that conolidine interacts With all the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availabi... https://eugener738kbq3.actoblog.com/profile